3 in 1 Combination COVID-19 Therapeutic Launches Late-Stage Study

In COVID-19, Latest News by Precision Vaccinations

A Massachusetts-based biopharmaceutical company announced that the U.S. Food and Drug Administrations (FDA) had approved the Company’s Investigational New Drug (IND) application to proceed with initiation of Phase 2 clinical trial of Brilacidin in hospitalized patients with COVID-19.
Brilacidin is a Host Defense Protein (HDP) mimetic representing a new class of drug with antiviral, anti-inflammatory, and anti-bacterial properties, said Innovation Pharmaceuticals.

Read More